Cftr Trikafta denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Requires Prior Authorization for Trikafta

Prior authorization (PA) is a mandatory pre-approval step BCBS imposes before covering high-cost specialty drugs. For CFTR modulator combination therapies, PA is nearly universal across commercial plans. A "prior auth required" denial typically means either the drug was dispensed or prescribed before authorization was obtained, or an authorization request was submitted but returned as incomplete or insufficient. This is not a clinical rejection of the therapy — it is an administrative gateway that can be navigated successfully with complete, well-organized documentation.

## Your Federal Appeal Rights

If a PA request was denied on clinical grounds, that denial is an adverse benefit determination subject to full appeal rights under ACA §2719 and ERISA §503. You have 180 days from the denial to file an internal appeal. After an internal denial, external independent review is available — typically within four months. For acute or urgent situations, an expedited PA and expedited appeal (typically resolved within 72 hours) is available when delay would seriously jeopardize health.

## The Concrete Appeal Process

1. Determine whether this is a new PA request or an appeal of a denied PA — the process differs. 2. For a new or resubmitted PA: complete BCBS's PA request form through the prescriber's office, ensuring all required clinical fields are populated. 3. For an appeal of a denied PA: file a written internal appeal within the deadline on the denial notice, attaching all clinical documentation. 4. If the internal appeal is denied, request independent external review through the IRO process described in your denial letter.

## Documentation to Gather

• Completed PA request form with all fields answered — incomplete forms are the most common reason PAs are rejected without clinical review
• Confirmed CFTR genotype report from a certified laboratory
• Prescriber's medical-necessity letter referencing the FDA-approved prescribing information and the applicable Cystic Fibrosis Foundation clinical care guidelines
• Pulmonary function test results and trend data showing clinical status and disease trajectory
• Prior treatment history with dates, agents used, and documented outcomes
• Clinical notes establishing diagnosis, symptom burden, and care timeline

## Criteria-Mapping Structure

Obtain BCBS's PA criteria for this drug class. Then answer each criterion explicitly:

| PA Criterion | Documentation Provided | |---|---| | Confirmed eligible CFTR genotype | Genetics lab report (lab name, date, result) | | Diagnosis of cystic fibrosis confirmed | Sweat chloride or genetic test on record | | Prescriber qualifications (CF specialist or coordination with one) | Provider credentials and referral notes | | Clinical severity or functional status | PFT trend, exacerbation history, chart notes | | Step-therapy requirements (if any) | Prior therapy history with dates and outcomes |

Every unanswered criterion becomes a reason for denial. Completing the mapping before submission prevents the most common PA failure mode.